Evidence map›Paper›PMID 36186213›Full record

ArticleWorld journal of clinical cases2022

Clinical efficacy analysis of mesenchymal stem cell therapy in patients with COVID-19: A systematic review.

Jun-Xia Cao, Jia You, Li-Hua Wu, Kai Luo, Zheng-Xu Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jun-Xia CaoBiotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
Jia YouBiotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
Li-Hua WuBiotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
Kai LuoBiotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China.
Zheng-Xu WangBiotherapy Center, The Seventh Medical Center of People's Liberation Army General Hospital, Beijing 100700, China. zhxuwang@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrently, ongoing trials of mesenchymal stem cells (MSC) therapies for coronavirus disease 2019 (COVID-19) have been reported.

aimIn this study, we investigated whether MSCs have therapeutic efficacy in novel COVID-19 patients.

methodsSearch terms included stem cell, MSC, umbilical cord blood, novel coronavirus, severe acute respiratory syndrome coronavirus-2 and COVID-19, applied to PubMed, the Cochrane Controlled Trials Register, EMBASE and Web of Science.

resultsA total of 13 eligible clinical trials met our inclusion criteria with a total of 548 patients. The analysis showed no significant decrease in C-reactive protein (CRP) levels after stem cell therapy (

conclusionOverall, our analysis suggests that while MSC therapy for COVID-19 patients does not significantly decrease inflammatory markers such as CRP, D-dimer and IL-6, OS is improved.

Indexed as

COVID-19Mesenchymal stem cellsMeta-analysisStem cell

Identifiers

PMID36186213
PMCPMC9516915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.